Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Copyright © 2024 Massachusetts Medical Society..
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:390 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 390(2024), 14 vom: 11. Apr., Seite 1290-1298 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Bryan D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Clinical Study |
|---|
| Anmerkungen: |
Date Completed 12.04.2024 Date Revised 20.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT05660369 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2314390 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369676823 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369676823 | ||
| 003 | DE-627 | ||
| 005 | 20240420232334.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240313s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2314390 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM369676823 | ||
| 035 | |a (NLM)38477966 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Bryan D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2024 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05660369 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Massachusetts Medical Society. | ||
| 520 | |a In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.) | ||
| 650 | 4 | |a Clinical Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a ErbB Receptors |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptors, Antigen, T-Cell |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Gerstner, Elizabeth R |e verfasserin |4 aut | |
| 700 | 1 | |a Frigault, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Leick, Mark B |e verfasserin |4 aut | |
| 700 | 1 | |a Mount, Christopher W |e verfasserin |4 aut | |
| 700 | 1 | |a Balaj, Leonora |e verfasserin |4 aut | |
| 700 | 1 | |a Nikiforow, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Bob S |e verfasserin |4 aut | |
| 700 | 1 | |a Curry, William T |e verfasserin |4 aut | |
| 700 | 1 | |a Gallagher, Kathleen |e verfasserin |4 aut | |
| 700 | 1 | |a Maus, Marcela V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 390(2024), 14 vom: 11. Apr., Seite 1290-1298 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:390 |g year:2024 |g number:14 |g day:11 |g month:04 |g pages:1290-1298 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2314390 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 390 |j 2024 |e 14 |b 11 |c 04 |h 1290-1298 | ||